Clinical trials: Normal Control
Scleroderma, Diffuse
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis…
- Trial name
- NCT06655896
- Testing
- rapcabtagene autoleucel, rituximab
- Where
- 93 sites in United States, Argentina and 20 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
- Trial name
- NCT04856917
- Testing
- Imsidolimab
- Where
- 15 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Vanda Pharmaceuticals
Alport Syndrome
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
The purpose of the study is to learn about the safety and tolerability of setanaxib in subjects with Alport syndrome, when added to their standard of care treatment.
- Trial name
- NCT06274489
- Testing
- Setanaxib
- Where
- 17 sites in Austria, Czechia and 3 more
- Volunteers
- 20 people
- Sponsor
- Calliditas Therapeutics AB
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to…
- Trial name
- NCT06553768
- Testing
- Maralixibat
- Where
- 23 sites in United States, Brazil and 8 more
- Volunteers
- 90 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Bone Loss
Comparison of Straumann Bone Ceramic and Bio-Oss With Guided Tissue Regeneration for Alveolar Ridge Preservation
The purpose of this study is to compare a new biomaterial with an already existing treatment principle (Bio-Oss/Bio-Gide) with regard to their ability to preserve the dimensions of the alveolar ridge and to promote bone…
- Trial name
- NCT00900718
- Testing
- Straumann Bone Ceramic, Bio-Oss
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Institut Straumann AG
HER2 + Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .
- Trial name
- NCT07601620
- Testing
- HLX319, EU-Phesgo®
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech
Onychomycosis
Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.
- Trial name
- NCT02343627
- Testing
- NVXT Solution, Vehicle of test product
- Volunteers
- 47 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 [NCT01519791].
- Trial name
- C-early (NCT01521923)
- Testing
- Certolizumab Pegol + Methotrexate (MTX)
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 359 people
- Sponsor
- UCB Pharma
Arthritis, Rheumatoid
Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis
The objective was to determine the effects of BIRB 796 BS on CRP and clinical parameters in Rheumatoid Arthritis as measures of efficacy, and on population pharmacokinetics and safety parameters
- Trial name
- NCT02209779
- Testing
- BIBR 796 BS
- Volunteers
- 167 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD I (NCT04242446)
- Testing
- Bimekizumab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 505 people
- Sponsor
- UCB Biopharma SRL
Triple Negative Breast Cancer
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of camrelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy in participants…
- Trial name
- NCT04613674
- Testing
- Camrelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 441 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Venous Ulcer
A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)
Venous leg ulcers are a common, costly and debilitating condition, with few effective treatments. Compression bandaging helps healing, but more than four out of every ten leg ulcers remain unhealed after three months.
- Trial name
- NCT00820196
- Testing
- Nexagon®, Nexagon® vehicle
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 98 people
- Sponsor
- OcuNexus Therapeutics, Inc.
Arthritis, Rheumatoid
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.
- Trial name
- NCT00413660
- Testing
- CP-690,550
- Where
- 82 sites in United States, Argentina and 11 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Uterine Fibroids
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with uterine fibroids.
- Trial name
- NCT01452659
- Testing
- TAK-385
- Where
- 27 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Takeda
Inflammation, Rheumatoid Arthritis
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0000 in subjects with…
- Trial name
- NCT01223911
- Testing
- NNC 0151-0000-0000
- Where
- 16 sites in Czechia, Denmark and 4 more
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Vitiligo
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
- Trial name
- NCT06905873
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Forte Biosciences, Inc.
Symptomatic Atrial Fibrillation, Atrial Flutter
Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo, in a dose modification manner, on the conversion of symptomatic atrial fibrillation (a-fib) or flutter of recent onset to normal sinus…
- Trial name
- COR-ART (NCT01691313)
- Testing
- Vanoxerine
- Where
- 6 sites in Israel, Russia
- Volunteers
- 104 people
- Sponsor
- Laguna Pharmaceuticals, Inc.
Androgenetic Alopecia
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss.
- Trial name
- NCT06590779
- Testing
- Aminexil® active+ lotion, Finasteride 1mg
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
This is a Phase 2, 3-week, single-center, double-blind, randomized, two-arm, vehicle controlled study, with each individual receiving both active and vehicle treatment.
- Trial name
- NCT03304470
- Testing
- ATx201 2% Cream, ATx201 Cream Vehicle
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- UNION therapeutics
Androgenic Alopecia, Alopecia
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia.
- Conditions
- Androgenic Alopecia, Alopecia, Baldness
- Trial name
- NCT07107841
- Testing
- Autologous Hair Follicle-Derived Secretome
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Acorn Biolabs Inc.